CorMedix Inc. Invited to Present at Two Upcoming Scientific Conferences
Bedminster, NJ –August 16, 2016 – CorMedix Inc. (NYSE MKT: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases, announced today that its executives have been invited to speak at two upcoming scientific and industry conferences. Chief executive officer Randy Milby will present at the 2016 World Anti-Microbial Resistance Congress and chief scientific officer Antony Pfaffle will participate on a panel at the Anti-Infectives Rx Conference.
Event: World Anti-Microbial Resistance Congress
Date: September 9
Time: 1:50p.m. – 2:05 p.m. (Eastern Time)
Location: Washington Court Hotel, Washington, D.C
Event: Anti-Infectives Rx Conference (Boston Biotech)
Panel: “Regulatory Landscape: What’s Needed to Drive Innovation?”
Date: September 21
Time: 1:50 p.m. – 2:20 p.m. (Eastern Time)
Location: Harvard Medical School-Joseph B. Martin Conference Center, Boston
About CorMedix Inc.
CorMedix Inc. is a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease. The Company is focused on developing its lead product Neutrolin®, a novel, non-antibiotic antimicrobial solution designed to prevent costly and dangerous bloodstream infections associated with the use of central venous catheters. Such infections cost the U.S. healthcare system approximately $6 billion annually and contribute significantly to increased morbidity and mortality. Neutrolin is currently in a Phase 3 clinical study in patients undergoing chronic hemodialysis via a central venous catheter. The company is planning to conduct its second Phase 3 study in patients with cancer receiving IV parenteral nutrition, chemotherapy and hydration via a chronic central venous catheter, subject to sufficient resources. If successful, the two pivotal studies may be submitted to the FDA for potential approval for both patient populations. Neutrolin has FDA Fast Track status and is designated as a Qualified Infectious Disease Product, contributing to potentially accelerated FDA review and up to 10 years of market exclusivity upon potential U.S. approval. It is already a CE Marked product in Europe and other territories. CorMedix is also seeking to unlock additional value for its taurolidine-based technology by establishing collaborative partnerships in oncology and medical device applications. For more information visit: www.cormedix.com.